CoChat

Semaglutide: First Global Approval

Dhillon, Sohita · 2018 · Drugs

The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.

Abstract

Novo Nordisk has developed a subcutaneous formulation of semaglutide (Ozempic®), a modified human glucagon-like peptide-1 (GLP-1) analogue, for the treatment of type 2 diabetes mellitus. It has been developed using Novo Nordisk's proprietary protein-acylation technology, and is administered using an injection device. Semaglutide lowers blood glucose by stimulating the release of insulin and also lowers body weight. Once-weekly subcutaneous semaglutide has recently been approved in the US, Puerto Rico and Canada, and has received a positive opinion in the EU for the treatment of patients with type 2 diabetes. It will be launched as the Ozempic® Pen, a pre-filled device. Semaglutide is also under regulatory review in Japan and Switzerland for the treatment of type 2 diabetes. Clinical development for obesity, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease is underway worldwide. This article summarizes the milestones in the development of semaglutide leading to this first approval for type 2 diabetes.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40265-018-0871-0

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Research works printed but not linked: 5

  1. Adis Insight. Drug profile: Semaglutide oral—Novo Nordisk. 2017. http://adisinsight.springer.com/drugs/800031465. Accessed 15 Dec 2017.
  2. Adis Insight. Drug profile: Semaglutide transdermal—Novo Nordisk 2017. http://adisinsight.springer.com/drugs/800050528. Accessed 15 Dec 2017.
  3. Raun K, Fels JJ, Rosenquist C, et al. Semaglutide, a once-weekly glucagon-like peptide 1 (GLP-1) analog, reduces bodyweight and promotes a more healthy food choice in diet-induced obese rats [abstract no. 1140-P]. Diabetes. 2015;64(Suppl 1):A293.
  4. Rakipovski G, Rolin B, Kirk R, et al. Long-acting GLP-1 receptor agonists semaglutide and liraglutide protect against development of atherosclerosis in animal models independent of body-weight-lowering effects [abstract no. 244-OR]. Diabetes. 2017;66(Suppl 1):A64.
  5. Arold G, Kupcova V, Jensen L, et al. Pharmacokinetics and tolerability of semaglutide in subjects with hepatic impairment [abstract no. 822]. Diabetologia. 2017;60(Suppl 1):S380–1.

Cited by

See all 112

Metadata

Authors
Dhillon, S.
Affiliations
Springer Nature (New Zealand) (NZ)
Corresponding author
Dhillon, Sohita
Venue
Drugs
Published
2018-01-23
Volume
78
Issue
2
Pages
275-284
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W2786178453
Cited by
104
References
19
Citations by year
2026: 14 · 2025: 18 · 2024: 21 · 2023: 12 · 2022: 7 · 2021: 9 · 2020: 8 · 2019: 9 · 2018: 6
FWCI
6.37
Type
journal article
Language
en
Open access
closed
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
semaglutide, type 2 diabetes, GLP-1 receptor agonists, protein acylation, subcutaneous formulation, Ozempic, drug approval, insulin secretion, weight loss, obesity, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease
MeSH terms
Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Insulin, Drug Approval

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Semaglutide: First Global Approval. https://app.cochat.ai/papers/10.1007/s40265-018-0871-0
The paper
Dhillon, S. (2018). Semaglutide: First Global Approval. Drugs. https://doi.org/10.1007/s40265-018-0871-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.